BioCentury
ARTICLE | Clinical News

Atara gains on Phase III plans for cell therapy

December 29, 2017 11:19 PM UTC

Atara Biotherapeutics Inc. (NASDAQ:ATRA) gained $2.85 (19%) to $18.10 Friday after FDA cleared the company to begin two Phase III trials of tabelecleucel (formerly ATA129) to treat Rituxan rituximab-refractory Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (EBV-PTLD). Atara said it will begin the open-label trials of the off-the-shelf T cell immunotherapy “imminently” and expects top-line data in 1H19.

The MATCH trial will evaluate tabelecleucel in EBV-PTLD patients who had an allogeneic hematopoietic cell transplant after failing Rituxan. The ALLELE trial will test the therapy in patients who had a solid organ transplant after failing Rituxan or Rituxan plus chemotherapy...

BCIQ Company Profiles

Atara Biotherapeutics Inc.